Mesalazin Orion

Mesalazine, the active ingredient in Mesalazin Orion, is an aminosalicylate (5‑ASA) presented as a rectal formulation for local use. It is employed to reduce inflammation in the colon of patients with ulcerative colitis and related disorders.

GNH USA supplies Mesalazin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazin Orion belongs to the aminosalicylate class and is used to manage inflammatory conditions of the colon. - Ulcerative colitis: reduces mucosal inflammation and helps achieve clinical remission. - Ulcerative proctitis: targets distal colonic inflammation to control symptoms. - Maintenance therapy: supports sustained remission in patients with ulcerative colitis after induction of response.

Mesalazin Orion may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea or mild vomiting - Headache - Flatulence or bloating - Increased bowel urgency

Serious or Rare Side Effects: - Severe allergic reaction (rash, swelling, anaphylaxis) - Acute severe colitis or bloody diarrhea - Hepatotoxicity (elevated liver enzymes) - Nephrotoxicity (renal function impairment) - Pancolitis flare - Blood dyscrasias (e.g., neutropenia)

Before initiating therapy, consider the following safety measures. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: caution advised; mesalazine may be excreted in milk. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly. - Concurrent infection: evaluate and treat infections before starting. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesalazin Orion can interact with several medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Azathioprine: may increase risk of bone‑marrow suppression. - Methotrexate: additive toxicity to hepatic and hematologic systems.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - NSAIDs: can exacerbate gastrointestinal irritation. - Live vaccines: immunogenic response may be reduced.